Browsing by Subject "pfizer"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Accountability in clinical trial diversity: The buck stops where?
    (Elsevier, 2021-06-01) Nephew, Lauren D.; Medicine, School of Medicine
    If the Pfizer and Moderna Coronavirus Disease (COVID-19) studies taught us one thing, it is that clinical trials can better reflect the diverse demographics of the population. Why then, do not most other Phase 3 clinical trials account for the diversity of the population who will most likely use the drug? Most do not, because there is no accountability. In developing the COVID-19 vaccine, industry and its partners were well aware of their mandate: develop a vaccine quickly that would be acceptable and legitimate to the public.